secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001193125-25-283294
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon reports Q3 net loss $17.5M; Phase 2 BESTOW positive; raises $57.5M
-------------------------------------------------------------------------

- Net loss $17.5M ($0.21/shr) vs net income $77M (incl $96.4M warrant gain) in Q3 2024.
- Cash & investments $93.4M at Sep 30, down from $140.2M at Dec 31, 2024.
- Phase 2 BESTOW: tegoprubart showed favorable safety, eGFR ~69 at 12 months; plans Phase 3 in 2026.
- Completed $57.5M public offering on Nov 13, net proceeds ~$53.6M to advance transplant programs.
- Anticipates FDA guidance on Phase 3 trial design for kidney transplantation in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000119312525283294/0001193125-25-283294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000119312525283294/eldn-20251114.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-283294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer